CME online

in association with the 6th Heart in Diabetes (HiD)

The Cardiorenal Metabolic Patient

This is a CME Symposium Supported by an Educational Grant from AstraZeneca
Provided By:

Administrated by::
This CME online educational activity is approved for a maximum of 1.75 AMA PRA Category 1 Credits ™.
Accreditation period: August 1, 2022 – August 1, 2023

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

The Primary Prevention of CHF and CKD in Diabetes
Agenda

Introduction & Pre-CME Questions
Yehuda Handelsman, MD

The Impact of CKD on Cardiovascular Disease
Janani Rangaswami, MD

The Prevention & Management of ASCVD in DM
Mikhail Kosiborod, MD

Contemporary Approach to the Management of CKD and HF
Stephen Greene, MD

Panel Discussion and Q&A: Case Based Comprehensive Management of the CardioRenal Patient
Case Presentation: Christian W. Mende, MD
Panel: Stephen Greene, MD • Mikhail Kosiborod, MD • Janani Rangaswami, MD
Moderator: Yehuda Handelsman, MD

Faculty

Mikhail N. Kosiborod MD, FACC, FAHA

Professor of Medicine Saint Luke's Mid America Heart Institute University of Missouri-Kansas City School of Medicine
Kansas City, Missouri


Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair & Program Director
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) / Heart in Diabetes (HID)
Chair & Founder
International Committee for Insulin Resistance
Tarzana, California

Janani Rangaswami MD

Professor of Medicine,
Director-Nephrology Fellowship and Cardiorenal Program,
George Washington University, DC

Christian W. Mende, MD, FACP, FACN, FASN, FASH, FAHA

Clinical Professor of Medicine
University of California San Diego
La Jolla, California

Stephen Greene, MD

Assistant Professor of Medicine
Cardiologist
Duke University School of Medicine
Duke Clinical Research Institute
Durham, North Carolina

Program Description

Recent cardiovascular outcome trials (CVOTs) have demonstrated prevention of ASCVD, HF & CKD in patients with and without diabetes. Of note sodium glucose cotransporter 2 (SGLT2) inhibitors and antiplatelet agents. The management of patients with HF & CKD is often limited by hyperkalemia which must be addressed when implementing therapy for the patient with multiple cardiorenal and metabolic conditions. Some therapies like SGLT2i have the potential to lower hyperkalemia however at times potassium binders are required.

In this CME satellite symposium, through a patient case, we will explore the complex challenges of treating patients with CKD, heart failure, and/or type 2 diabetes (T2D) who also have or are at risk for ASCVD. Specifically we'll address clinicians’ gaps in knowledge of the interconnections between CKD, ASCVD, heart failure, and T2D and the required comprehensive management of these conditions when presented in the same patient.




Learning Objectives

Upon completion of this CME symposium, participants should be able to:

  • Discuss CKD epidemiology and pathophysiologic interactions with CVD, diabetes, and other cardiometabolic conditions
  • Describe the benefits and limitations of antiplatelet therapy for the primary prevention of ASCVD events in people with diabetes
  • Compare and contrast the benefits and limitations of established and emerging treatments for CKD and heart failure
  • Develop management strategies for patients with complicated disease, including those with CKD, ASCVD, diabetes, and heart failure

    • Target Audience

    This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of CKD and HF and prevention of morbidity and mortality.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI Inc., is accredited by the ACCME to provide continuing medical education for physicians.

    PESI, Inc, designated this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s).

    For information please contact: [email protected] or 818 342 1889